{ "$schema_version": "5.4", "review_mode": "fresh", "claim_restatement": { "index_wording": "Persistent infection with a high-risk HPV genotype is a necessary cause of HPV-associated cervical carcinoma.", "entry_form": "claim", "gradeable_restatement": "Among primary invasive cervical squamous carcinomas and usual-type endocervical adenocarcinomas classified by anatomy and histomorphology before HPV-result review, development of the common HPV-associated pathway requires prior type-specific persistent infection with a carcinogenic HPV genotype; preventing that infection should markedly reduce the corresponding cancers.", "restatement_required": true, "split_into": [ "SC1: prospective temporality and persistence", "SC2: etiologic necessity in independently specified common histologies", "SC3: continued E6/E7 maintenance dependence", "SC4: preventive intervention and pathway interruption", "SC5: reproducible boundary from HPV-independent cervical carcinomas" ], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "HPV-associated", "determinable_before_outcome": false, "determined_from": "As written, the phrase is often assigned from HPV or p16 positivity in the tumour and therefore builds the causal exposure into the disease label.", "action": "replaced with measurable antecedent" }, { "qualifier": "primary invasive cervical squamous carcinoma and usual-type endocervical adenocarcinoma", "determinable_before_outcome": true, "determined_from": "anatomic primary-site review and prespecified histomorphology performed before HPV assay results are examined", "action": "retained" }, { "qualifier": "type-specific persistent infection", "determinable_before_outcome": true, "determined_from": "repeat detection of the same carcinogenic genotype before neoplasia, or concordant tumour/precursor molecular evidence when prospective samples are unavailable", "action": "replaced with measurable antecedent" } ] }, "lay_summary": { "paragraphs": [ "Overall grade: Θ (theta), high predictive accuracy with minimal unresolved exceptions; confidence is High. Persistent infection with a cancer-causing HPV type is the primary upstream cause of nearly all common squamous and usual-type glandular cervical cancers. Persistence is not enough by itself: most infections clear, and host, immune, smoking, and genomic factors influence which persistent infections progress.", "The strongest evidence comes from three directions that fail differently. Repeated detection of the same HPV type years before disease predicts cervical cancer far better than a single or cleared infection. Vaccination before exposure prevents high-grade precancer in randomized trials and has been followed by large reductions in invasive cancer. Turning off the viral E6/E7 genes reverses the transformed state in several experimental systems.", "The wording needs one correction. If 'HPV-associated' simply means HPV-positive, the statement is circular. When the common histologies are defined independently before the HPV result, the model remains highly accurate but not logically exception-free: rare HPV-independent squamous cancers and established HPV-independent glandular types exist. The claim therefore reaches Θ, not Ω, and HPV is necessary in the common pathway without being sufficient on its own." ], "grade_restated_faithfully": true, "claims_referenced": [ "C1", "C4", "C7", "C8", "C9", "C10", "C11", "C16", "C17", "C22", "C24", "C25", "C26" ], "jargon_glossed": [ "high-risk or carcinogenic HPV", "persistence", "E6/E7", "HPV-independent" ], "no_practical_advice": true, "written_for": "an educated nonspecialist assessing causal evidence" }, "hypothesis": { "name": "Persistent high-risk HPV as a necessary cause of HPV-associated cervical carcinoma", "central_claim": "Persistent infection with a carcinogenic HPV genotype is required in the causal history of HPV-associated cervical carcinoma.", "proposed_mechanism": "Persistent viral E6/E7 expression disables p53- and Rb-centred tumour-suppressive control, permits clonal evolution, and maintains many established HPV-associated tumour cells.", "claimed_scope": "HPV-associated cervical carcinoma", "claimed_level": [ "initiation", "maintenance", "progression", "response" ], "is_conjunctive": true, "conjunctive_note": "The sentence joins persistent exposure, strict etiologic necessity, tumour-class scope, and an implied mechanism. Prevention and continued E6/E7 dependence are tested separately so evidence for one is not borrowed by another." }, "rubric_routing": { "primary_rubric": "02-cancer-biology.md", "secondary_rubrics": [], "index_notes_applied": [ "No HPV-specific hypothesis-index entry was present in the supplied packet.", "Cross-field check: 05-immunology-inflammation was considered because the exposure is a persistent viral infection, but it does not govern any subclaim (host immunity enters only as a progression cofactor, not as the graded mechanism). Both rubrics place Η/Θ/Ω as live options, so the cross-field lowest-ceiling rule imposes no lower ceiling." ], "rubric_fit_note": "The cancer-biology rubric explicitly names 'a persistent infection and a carcinoma' as a near-top-ladder causal claim and permits prophylactic perturbation with an incidence endpoint, cohort dose-response, and population natural experiments where a mechanism RCT is unethical or infeasible. The immunology-inflammation rubric was checked and is non-governing; the claim is viral-oncogene-driven carcinogenesis rather than an inflammation-first model, and neither rubric caps the level below the assigned Θ." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Type-specific carcinogenic HPV infection precedes cervical neoplasia, and sustained detection rather than a single transient infection identifies the high-risk causal exposure.", "subclaim_type": "temporality", "governing_rubric": "02-cancer-biology.md", "claimed_scope": "natural history before squamous or usual-type cervical carcinoma", "scope": "Prospective cohorts with HPV measured in cytologically normal women before CIN3, carcinoma in situ, or invasive carcinoma; transient and cleared infection remain internal negative controls.", "key_evidence_anchor": "Prospective type-specific repeated-testing cohorts with long-term histologic or registry outcomes.", "hsef_level": "Θ", "confidence": "High", "governing_cap_or_threshold": "Prospective temporality, type specificity, duration gradient, and repeated independent cohorts satisfy Θ with few directional exceptions.", "rationale": "Persistent same-type infection precedes disease and predicts orders-of-magnitude greater risk than repeated negativity. Most infections clear, so this establishes the exposure pattern without claiming sufficiency." }, { "id": "SC2", "statement": "Prior persistent carcinogenic HPV is an etiologic requirement for the common squamous and usual-type endocervical carcinoma pathways when those histologies are specified before the viral assay.", "subclaim_type": "necessity", "governing_rubric": "02-cancer-biology.md", "claimed_scope": "common independently specified cervical carcinoma histologies", "scope": "Primary invasive cervical squamous carcinoma and usual-type endocervical adenocarcinoma assigned by anatomy and histomorphology before HPV-result review; rare gastric-type, clear-cell, mesonephric, endometrioid, and demonstrably HPV-independent squamous carcinomas are retained as negative controls rather than relabeled.", "key_evidence_anchor": "Sensitive multi-target tumour testing, morphology-first classification, prevention before infection, and reproducible true-negative boundary cases.", "hsef_level": "Θ", "confidence": "High", "governing_cap_or_threshold": "The causal model predicts nearly all common-pathway tumours and prevention effects, but true HPV-independent SCC and discordant usual-type tumours block exception-free necessity and Ω.", "rationale": "Prospective persistence, near-universal tumour attribution after quality control, and vaccine prevention converge. The literal Boolean word 'necessary' is too absolute across all cervical carcinomas, and 'HPV-associated' is circular if defined only by a positive HPV result." }, { "id": "SC3", "statement": "Continued E6/E7 expression maintains the transformed phenotype after an HPV-associated cervical tumour is established.", "subclaim_type": "mechanism", "governing_rubric": "02-cancer-biology.md", "claimed_scope": "maintenance of established HPV16/18-positive cervical tumour models and primary cells", "scope": "Conditional autochthonous HPV16-E7 mouse tumours, resident E6/E7 repression in cervical cancer cells, low-passage primary tumour cells, and genotype-matched CRISPR perturbation; human therapeutic dependence is not assumed.", "key_evidence_anchor": "Endogenous viral-oncogene loss of function with matched specificity controls, in-vivo regression, and eventual human therapeutic targeting.", "hsef_level": "Η", "confidence": "High", "governing_cap_or_threshold": "Strong in-vivo conditional dependency plus independent primary-cell and genetic loss-of-function evidence satisfy Η; absence of broad human therapeutic ablation and HPV-inactive exceptions block Θ.", "rationale": "Multiple perturbations restore p53/Rb control, induce senescence or death, and regress lesions in a conditional cervical model. This stronger maintenance claim supports mechanism but is not required for prior etiologic necessity." }, { "id": "SC4", "statement": "Preventing acquisition of carcinogenic HPV, or detecting and treating its precursor pathway, reduces high-grade cervical neoplasia and invasive cervical carcinoma.", "subclaim_type": "reversibility", "governing_rubric": "02-cancer-biology.md", "claimed_scope": "human prevention before infection and population cervical-cancer incidence", "scope": "Randomized prophylactic vaccine trials in susceptible participants, national age-at-offer natural experiments with invasive cancer, and randomized HPV-screening trials; pre-existing infection is separated from prophylaxis.", "key_evidence_anchor": "Virus-specific randomized prophylaxis followed by independent invasive-cancer incidence reductions.", "hsef_level": "Θ", "confidence": "High", "governing_cap_or_threshold": "Randomized type-matched precursor prevention and replicated invasive-cancer population effects satisfy Θ; long latency prevents a single randomized invasive-cancer trial.", "rationale": "Two vaccine platforms prevent type-attributed CIN3/AIS in susceptible women, and national programmes show the predicted age-at-vaccination gradient for invasive cancer. Screening RCTs provide a separate pathway-interruption line." }, { "id": "SC5", "statement": "The HPV-associated causal pathway and its HPV-independent boundary can be mapped reproducibly without deleting discordant tumours after their viral result is known.", "subclaim_type": "generalization", "governing_rubric": "02-cancer-biology.md", "claimed_scope": "squamous and glandular cervical carcinoma classification", "scope": "Morphology-first adenocarcinoma classification, centralized squamous review, p16 and HPV RNA/DNA assays, specimen-quality reassessment, and genomics; morphology overlap in squamous disease is retained.", "key_evidence_anchor": "Independent morphology-first validation plus multi-assay characterization of genuine and technical HPV-negative cases.", "hsef_level": "Η", "confidence": "High", "governing_cap_or_threshold": "Reproducible histotype boundaries and molecularly distinct negative controls meet Η, but squamous morphology overlap and assay dependence block Θ.", "rationale": "Adenocarcinoma boundaries are strongly reproducible from morphology before HPV testing. Rare HPV-independent squamous carcinoma is real, but morphology alone does not perfectly identify it, so the report does not make 'HPV-associated' a post hoc rescue label." } ], "aggregation_rule": "primary-subclaim", "aggregation_preregistered": true, "aggregation_rationale": "The submitted proposition is specifically a necessity claim, so SC2 is grade-fixing. SC1 and SC4 are required independent supports and may lower the result if they fail; SC3 tests a stronger maintenance claim, and SC5 tests whether the scope can be bounded without circular relabeling.", "primary_subclaim_id": "SC2", "aggregation_derivation": "SC1=Θ; SC2=Θ; SC3=Η; SC4=Θ; SC5=Η. The preregistered primary-subclaim rule returns SC2=Θ; SC1 and SC4 support rather than lower it, SC3 is a stronger non-gating claim, and SC5 supplies explicit negative controls.", "aggregation_alternatives": { "weakest_link_would_return": "Η", "primary_subclaim_would_return": "Θ", "scope_matched_would_return": "Θ", "note": "Weakest-link would lower the bundle because human tumour-wide E6/E7 ablation and morphology-only squamous classification remain incomplete. That would answer the stronger conjunction, not the submitted etiologic-necessity question." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M1", "is_nominal": true, "name": "Persistent carcinogenic-HPV necessary-cause model", "core_claim": "Type-specific persistent carcinogenic HPV is the indispensable upstream exposure in the common HPV-associated cervical-cancer pathway, while host cofactors govern progression.", "explains_what_nominal_does_not": "The refined form explicitly separates necessity from sufficiency and prespecifies the common histologic scope.", "strongest_supporting_evidence": [ "Prospective persistence [3-5,22]", "vaccine and screening interventions [7-10,21,23]", "multi-assay tumour attribution [1,2,6,15,16]" ], "strongest_contradictory_evidence": [ "Rare HPV-independent SCC [17,24,25]", "a residual HPV-undetected group after retesting [18,19]" ], "hsef_level_for_this_model": "Θ", "rationale": "Temporality, type specificity, prevention, tumour attribution, and viral-oncogene loss of function converge. The model predicts the common pathway with very few exceptions once independently recognized HPV-independent histotypes are retained, but those exceptions and absence of sufficiency prevent Ω." }, { "rank_in_tournament": 2, "model_id": "M4", "is_nominal": false, "name": "Histotype-mixture and technical-false-negative model", "core_claim": "Most apparent HPV-negative exceptions are either genuine HPV-independent cervical tumour classes, noncervical mimics, poor specimens, or assay failures rather than failures of the common HPV-driven pathway.", "explains_what_nominal_does_not": "It explains why crude HPV-negative fractions vary by histology, specimen age, tissue quality, and assay target.", "strongest_supporting_evidence": [ "Multi-target reanalysis [1,18]", "TCGA endometrial-like negatives [15]", "morphology-first IECC [16,20]", "true HPVI SCC [17,24,25]" ], "strongest_contradictory_evidence": [ "Morphology alone does not perfectly separate squamous classes", "some HPV-undetected tumours remain biologically ambiguous [19]" ], "hsef_level_for_this_model": "Θ", "rationale": "This model is nearly as well supported as M1 and is complementary rather than mutually exclusive. It wins the explanation of apparent negatives but does not replace the prospective and preventive evidence for HPV causality." }, { "rank_in_tournament": 3, "model_id": "M3", "is_nominal": false, "name": "Host-first permissive model", "core_claim": "Host genomic instability, immune failure, smoking, hormonal exposure, or tissue state is primary, while HPV is a frequent passenger or accelerator.", "explains_what_nominal_does_not": "It explains why most infections clear and why only a minority of persistent infections progress.", "strongest_supporting_evidence": [ "Low absolute progression despite common infection [22]", "genomically distinct HPV-independent tumours [15,19,24,25]" ], "strongest_contradictory_evidence": [ "Virus-specific prophylaxis prevents lesions and invasive cancer [7-10,23]", "E6/E7 loss reverses transformed phenotypes [11-14]" ], "hsef_level_for_this_model": "Η", "rationale": "Host factors are causally important modifiers and may be primary in HPV-independent tumours. As a complete account of common HPV-associated carcinoma, the model fails to explain type-specific persistence, vaccination effects, and oncogene dependence." }, { "rank_in_tournament": 4, "model_id": "M5", "is_nominal": false, "name": "Incomplete carcinogenic-genotype-set model", "core_claim": "Persistent papillomavirus remains causal, but accepted high-risk panels omit rare causal genotypes or occasional nominally low-risk types.", "explains_what_nominal_does_not": "It can explain a small subset of assay-negative or noncanonical-genotype tumours without invoking HPV-independent oncogenesis.", "strongest_supporting_evidence": [ "Rare sequenced types in worldwide tumours [6]", "risk heterogeneity across carcinogenic types [2,22]" ], "strongest_contradictory_evidence": [ "p16-negative, broad-assay-negative, genomically distinct HPV-independent tumours [17,24,25]" ], "hsef_level_for_this_model": "Ε", "rationale": "Rare genotype-panel misses are real and context-specific. They cannot explain all well-characterized HPV-independent glandular and squamous tumours, so the model is a narrow supplement." }, { "rank_in_tournament": 5, "model_id": "M2", "is_nominal": false, "name": "Transient hit-and-run model", "core_claim": "HPV initiates transformation but can later be lost, leaving a truly virus-negative descendant still caused by prior infection.", "explains_what_nominal_does_not": "It could reconcile an HPV-driven origin with tumours lacking current viral DNA, RNA, or oncogene activity.", "strongest_supporting_evidence": [ "Existence of HPV-undetected cervical tumours [18,19]", "viral integration and genomic evolution [15]" ], "strongest_contradictory_evidence": [ "Most sensitive-test negatives resolve into technical failures or distinct histotypes [1,15-18,20]", "no lineage-resolved human proof of prior virus followed by complete loss" ], "hsef_level_for_this_model": "Γ", "rationale": "The model is plausible but lacks the lineage evidence needed to distinguish genuine viral loss from misclassification, assay failure, or independent oncogenesis. It cannot carry a broad causal exception claim." } ], "tournament_summary": "The refined persistent-HPV model ranks first at Θ, with the histotype-mixture/technical-false-negative model a close, complementary second. Host cofactors explain progression conditional on infection but do not displace HPV in the common pathway. The nominal model ranks 1 of 5.", "study_separating_rank1_from_rank2": "The Chen 16-year prospective persistence cohort [4] separates the causal model from a classification-only explanation because HPV status was measured before carcinoma; the IECC morphology-first study [16] then separates true pathway boundaries from post hoc relabeling.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "citation": "Kjaer et al. 2002; Chen et al. 2011; Schiffman et al. 2011; Demarco et al. 2020", "source_pointer": "PMIDs 12228133, 21900119, 21602310, 32510043; refs [3-5,22]", "relates_to_subclaims": [ "SC1", "SC2", "SC5" ], "favors_models": [ "M1", "M3" ], "evidence_class": "Strong", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Type-specific persistence precedes high-grade disease and carcinoma and sharply separates risk from clearance or repeated negativity.", "what_it_does_not_show": "It does not show that persistence is sufficient, and some endpoints combine CIN3 or carcinoma in situ with invasive cancer.", "confounders_present": [ "screening and treatment during follow-up", "loss to repeat testing", "type assay differences", "combined precursor and cancer endpoints" ], "verification": "verified", "verification_note": "All four primary records were checked; complete full text was read for each.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [ "Scite was unavailable by user report; citation-context counts were intentionally omitted." ] }, "source_tier": "A" }, { "citation": "Walboomers et al. 1999", "source_pointer": "PMID 10451482; ref [1]", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Strong", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Multi-target testing and pathology-quality review converted most formerly HPV-negative tumours to positive and yielded 99.7% prevalence among adequate samples.", "what_it_does_not_show": "It does not erase later-recognized HPV-independent histotypes or prove prior persistence in every tumour.", "confounders_present": [ "retrospective tissue", "selected reanalysis", "historic classification", "assay sensitivity" ], "verification": "verified", "verification_note": "The PubMed primary abstract and all reported denominators were checked.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [ "Scite was unavailable by user report; citation-context counts were intentionally omitted." ] }, "source_tier": "A" }, { "citation": "Muñoz et al. 2003; de Sanjose et al. 2010", "source_pointer": "PMIDs 12571259, 20952254; refs [2,6]", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [ "M1", "M5" ], "evidence_class": "Strong", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Large multi-country datasets establish the magnitude, genotype specificity, and worldwide distribution of the HPV-cervical-cancer association.", "what_it_does_not_show": "Tumour detection is retrospective and cannot by itself distinguish persistence, technical false negatives, or HPV-independent histotypes.", "confounders_present": [ "specimen quality", "histotype mix", "PCR target differences", "geographic sampling" ], "verification": "verified", "verification_note": "Both PubMed primary abstracts, assay descriptions, and numerical results were checked.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [ "Scite was unavailable by user report; citation-context counts were intentionally omitted." ] }, "source_tier": "A" }, { "citation": "FUTURE II Study Group 2007", "source_pointer": "PMID 17494925; ref [7]", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Randomized virus-specific prophylaxis in susceptible women prevented HPV16/18-attributed high-grade cervical lesions in the predicted direction.", "what_it_does_not_show": "The follow-up was too short for invasive cancer and the all-randomized population included pre-existing infection.", "confounders_present": [ "precursor endpoint", "per-protocol susceptibility", "short cancer latency" ], "verification": "verified", "verification_note": "The PubMed RCT abstract, population definitions, endpoint, and effect estimates were checked.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [ "Scite was unavailable by user report; citation-context counts were intentionally omitted." ] }, "source_tier": "A" }, { "citation": "Lehtinen et al. 2012 (PATRICIA)", "source_pointer": "PMID 22075171; ref [8]", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "A second randomized vaccine platform prevented type-matched CIN3+ and reduced all-type CIN3+ in HPV-naive women.", "what_it_does_not_show": "It does not directly randomize invasive-cancer incidence over decades or establish that every prevented all-type lesion was caused by a vaccine genotype.", "confounders_present": [ "precursor endpoint", "cross-protection", "endpoint attribution", "short cancer latency" ], "verification": "verified", "verification_note": "The PubMed RCT abstract, endpoint definitions, and efficacy estimates were checked; the erratum flag is retained.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [ "Scite was unavailable by user report; citation-context counts were intentionally omitted." ] }, "source_tier": "A" }, { "citation": "Lei et al. 2020; Falcaro et al. 2021 and 2025; Palmer et al. 2024", "source_pointer": "PMIDs 32997908, 34741816, 39759575, 38247547; refs [9,10,23,26]", "relates_to_subclaims": [ "SC2", "SC4", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "natural experiment", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "National programmes in Sweden, England, and Scotland show large invasive-cancer reductions and the predicted advantage of vaccination before likely exposure, including no recorded invasive cancers among Scottish women vaccinated at age 12-13.", "what_it_does_not_show": "The studies are not individually randomized, and the two England reports are one programme line with overlapping cohorts.", "confounders_present": [ "vaccine uptake selection", "screening changes", "secular trends", "registry coding" ], "verification": "verified", "verification_note": "PubMed abstracts were checked for Sweden, the first England report, and Scotland; complete PMC full text was read for the updated England analysis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [ "Scite was unavailable by user report; citation-context counts were intentionally omitted." ] }, "source_tier": "A" }, { "citation": "Ronco et al. 2014", "source_pointer": "PMID 24192252; ref [21]", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Randomized HPV-based screening followed by management reduced invasive cervical cancer compared with cytology-based screening.", "what_it_does_not_show": "This tests detection and removal of the precursor pathway, not whether HPV is sufficient or whether screening benefit is mediated only by the viral assay.", "confounders_present": [ "pooled protocols", "downstream treatment", "screening contamination", "interval cancer" ], "verification": "verified", "verification_note": "The PubMed abstract, trial pool, endpoint count, and effect estimates were checked; the erratum is linked.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [ "Scite was unavailable by user report; citation-context counts were intentionally omitted." ] }, "source_tier": "A" }, { "citation": "Jabbar et al. 2009", "source_pointer": "PMID 19435895; ref [11]", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Conditional repression of HPV16 E7 in an autochthonous cervical model regressed dysplasia and established tumours.", "what_it_does_not_show": "A transgenic estrogen-supported model cannot establish human tumour-wide therapeutic dependence or natural viral history.", "confounders_present": [ "transgene expression", "mouse species", "estrogen cofactor", "engineered reversibility" ], "verification": "verified", "verification_note": "Complete PMC full text, conditional design, pathology, and outcomes were read.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [ "Scite was unavailable by user report; citation-context counts were intentionally omitted." ] }, "source_tier": "A" }, { "citation": "Goodwin et al. 2000; DeFilippis et al. 2012; Kennedy et al. 2014", "source_pointer": "PMIDs 11005870, 22056390, 25100830; refs [12-14]", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "ex vivo", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Independent repression or cleavage of resident E6/E7 restores tumour-suppressor control and induces senescence, arrest, or death, including in low-passage primary tumour cells.", "what_it_does_not_show": "These interventions remain cell-based and lack matched human in-vivo rescue or broad clinical response evidence.", "confounders_present": [ "cell adaptation", "delivery toxicity", "genotype restriction", "absence of intact microenvironment" ], "verification": "verified", "verification_note": "Complete PMC full text was read for all three studies, including controls and limitations.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [ "Scite was unavailable by user report; citation-context counts were intentionally omitted." ] }, "source_tier": "A" }, { "citation": "Cancer Genome Atlas Research Network 2017", "source_pointer": "PMID 28112728; ref [15]", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [ "M1", "M3", "M4" ], "evidence_class": "Strong", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Viral and genomic profiling identifies a large HPV-positive majority and a distinct HPV-negative endometrial-like group.", "what_it_does_not_show": "TCGA selection does not estimate population prevalence and cannot prove the causal history of every HPV-undetected tumour.", "confounders_present": [ "cohort selection", "cross-sectional tumour profiling", "viral-expression threshold", "site-of-origin classification" ], "verification": "verified", "verification_note": "Complete PMC full text, cohort table, viral analysis, and molecular subgroup results were read.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [ "Scite was unavailable by user report; citation-context counts were intentionally omitted." ] }, "source_tier": "A" }, { "citation": "Stolnicu et al. 2018; Hodgson et al. 2020", "source_pointer": "PMIDs 29135516, 32854489; refs [16,20]", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Strong", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Morphology assigned before HPV results reproducibly separates usual-type HPV-associated from gastric, clear-cell, mesonephric, and other HPV-independent adenocarcinoma pathways.", "what_it_does_not_show": "Morphology is imperfect, some usual-type tumours remain HPV-negative, and the validation cohorts are pathology-enriched rather than population samples.", "confounders_present": [ "expert pathology", "tissue processing", "assay sensitivity", "referral cohort" ], "verification": "verified", "verification_note": "Complete PMC full text, classification criteria, validation tables, discordant cases, and limitations were read.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [ "Scite was unavailable by user report; citation-context counts were intentionally omitted." ] }, "source_tier": "A" }, { "citation": "Stolnicu et al. 2023 and 2025; Kır et al. 2025", "source_pointer": "PMIDs 37702216, 40010435, 40347270; refs [17,24,25]", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [ "M3", "M4" ], "evidence_class": "Strong", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "Independent pathology, p16, broad HPV testing, and genomic characterization establish a rare HPV-independent cervical SCC class.", "what_it_does_not_show": "Selected case series cannot provide a single population prevalence, and p16/HPV assays remain test-dependent.", "confounders_present": [ "case selection", "morphologic overlap", "assay dependence", "small molecular series" ], "verification": "verified", "verification_note": "Complete PMC full text was read for the 2023 cohort and six-case 2025 series; the 2025 multicentre abstract and definitions were checked.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [ "Scite was unavailable by user report; citation-context counts were intentionally omitted." ] }, "source_tier": "A" }, { "citation": "Kaliff et al. 2020; Banister et al. 2021", "source_pointer": "PMIDs 31206367, 34572780; refs [18,19]", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [ "M2", "M3", "M4" ], "evidence_class": "Strong", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "Retesting resolves many apparent negatives, while a residual HPV-undetected group has distinct clinicogenomic features.", "what_it_does_not_show": "The studies cannot prove that every residual negative was never infected or that every HPV-undetected tumour belongs to one mechanism.", "confounders_present": [ "archival degradation", "assay target loss", "histotype mixture", "selected HPV-undetected cohort" ], "verification": "verified", "verification_note": "Complete PMC full text, repeat-testing workflow, genomics, outcomes, and caveats were read.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [ "Scite was unavailable by user report; citation-context counts were intentionally omitted." ] }, "source_tier": "A" } ], "verification_summary": { "load_bearing_claims_checked": 27, "verified": 27, "unverified": 0, "contradicted": 0, "note": "All 27 registered claims were checked against Tier A primary records. Sixteen of 26 sources were read in complete full text; ten were limited to PubMed abstract and metadata and are labeled accordingly. The cross-model red team re-resolved every identifier and re-confirmed the headline numeric claims against primary sources; two full-text-only sub-figures (claim C4 cumulative risks; claim C15 TCGA counts) were retained on their confirmed headline values. Contradictory evidence is verified evidence against the universal form, not a contradicted citation claim." }, "factual_issues_found": [ { "quoted_text": "HPV-associated cervical carcinoma", "problem": "If HPV-associated is assigned solely from a positive HPV assay or p16 surrogate after cancer is observed, the scope contains the causal exposure and makes necessity true by definition.", "source_says": "Morphology-first IECC studies can classify major glandular pathways before HPV testing, while modern squamous studies show true HPV-independent tumours and substantial morphologic overlap.", "source_pointer": "PMIDs 29135516, 32854489, 37702216, 40010435, 40347270", "affects_score": true, "action": "scored-on-corrected-understanding" }, { "quoted_text": "necessary cause", "problem": "In strict logic, one genuine in-scope counterexample defeats necessity. Modern pathology recognizes rare HPV-independent squamous carcinoma as well as several HPV-independent glandular classes.", "source_says": "The common HPV-driven pathway has near-universal attribution, but a 2% HPV-independent fraction was observed in one tested SCC cohort and larger selected series confirm the entity.", "source_pointer": "PMIDs 37702216, 40010435, 40347270", "affects_score": true, "action": "scored-on-corrected-understanding" } ], "cap_rules_applied": [ { "subclaim_id": "SC1", "cap": "Β", "cap_source": "rubric", "triggered": false, "trigger_text_quoted": "Association-only cancer claims cap at Β.", "specific_trigger": "Prospective repeated testing establishes temporal order and is combined with independent prevention evidence; the final inference is not association-only.", "resulting_ceiling": "Ω" }, { "subclaim_id": "SC2", "cap": "Γ", "cap_source": "rubric", "triggered": false, "trigger_text_quoted": "Mechanistically plausible cell culture or transplantation-linked models without endogenous in vivo dependency cap at Γ.", "specific_trigger": "The etiologic claim rests on human prospective cohorts, prophylactic interventions, population cancer incidence, and tumour classification, not cell culture or transplantation alone.", "resulting_ceiling": "Ω" }, { "subclaim_id": "SC3", "cap": "Γ", "cap_source": "rubric", "triggered": false, "trigger_text_quoted": "In vitro-only mechanistic studies, however elegant", "specific_trigger": "Several E6/E7 studies are in vitro, but a conditional autochthonous cervical-tumour model shows positive in-vivo regression; the inference is restricted to model and primary-cell maintenance rather than universal human therapeutic dependence.", "resulting_ceiling": "Ω" }, { "subclaim_id": "SC4", "cap": "Β", "cap_source": "rubric", "triggered": false, "trigger_text_quoted": "Association-only cancer claims cap at Β.", "specific_trigger": "Two randomized prophylactic vaccine trials and randomized HPV-screening follow-up directly change disease endpoints; national cancer-incidence studies provide longer-latency convergence.", "resulting_ceiling": "Ω" }, { "subclaim_id": "SC5", "cap": "Γ", "cap_source": "rubric", "triggered": false, "trigger_text_quoted": "Broad generalization across tumor types", "specific_trigger": "The review does not generalize across all cervical carcinomas. It maps glandular and squamous boundaries and preserves HPV-independent tumours as internal negative controls.", "resulting_ceiling": "Ω" } ], "cap_precedence_resolutions": [ { "collision": "Prospective tumour association would cap at Β if scored alone, while the cancer rubric names prophylactic incidence effects and population dose-response as upper-ladder equivalents.", "subclaim_scope_cap_binds_on": "A single retrospective HPV-positive tumour series cannot establish necessity beyond association.", "subclaim_scope_threshold_binds_on": "The convergent human set includes prospective persistence, randomized virus-specific prophylaxis, invasive-cancer natural experiments, and mechanistic loss of function.", "resolution": "The association cap remains on the retrospective rows; it is not re-applied to an evidence set assembled from classes with different failure modes.", "note": "This follows the rubric's explicit instruction: 'Convergence is not re-capped.'" }, { "collision": "In-vitro E6/E7 loss of function would cap a maintenance inference at Γ, while conditional in-vivo E7 repression crosses the causal threshold in that model.", "subclaim_scope_cap_binds_on": "Human tumour-wide maintenance inferred from cell lines alone.", "subclaim_scope_threshold_binds_on": "Established dysplasia and tumours in the conditional autochthonous mouse model, with independent primary-cell support.", "resolution": "SC3 is scored across its stated model and primary-cell scope at Η, while broad human therapeutic dependence remains an explicit gap.", "note": "The in-vitro rows do not independently carry the human claim." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "Field-valid equivalents in this domain: cohort dose-response across independent populations, withdrawal-and-rechallenge at population scale (exposure cessation followed by incidence decline), germline or somatic genetic natural experiments, and prophylactic or therapeutic perturbation with an incidence or survival endpoint.", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "Prospective cohort dose-duration evidence [3-5,22] plus prophylactic intervention [7,8].", "gamma_hard_rules_triggered": [ "Sphere formation alone — not triggered.", "Marker enrichment alone — not triggered.", "Xenograft tumor-initiation without lineage-resolved endogenous evidence — not triggered.", "In vitro-only mechanistic studies, however elegant — not triggered for the scored convergent set; SC3 includes an autochthonous conditional in-vivo model, while the in-vitro rows are not used alone." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Persistence predicts CIN3/carcinoma and prevention changes high-grade disease; transient infection is an internal negative control.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "Field-valid equivalents in this domain: cohort dose-response across independent populations, withdrawal-and-rechallenge at population scale (exposure cessation followed by incidence decline), germline or somatic genetic natural experiments, and prophylactic or therapeutic perturbation with an incidence or survival endpoint.", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "Randomized prophylactic vaccination [7,8], invasive-cancer natural experiments [9,10,23], and morphology-first tumour classification [16,20].", "gamma_hard_rules_triggered": [ "Sphere formation alone — not triggered.", "Marker enrichment alone — not triggered.", "Xenograft tumor-initiation without lineage-resolved endogenous evidence — not triggered.", "In vitro-only mechanistic studies, however elegant — not triggered for the scored convergent set; SC3 includes an autochthonous conditional in-vivo model, while the in-vitro rows are not used alone." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Virus-specific prevention changes high-grade precursor and invasive-cancer incidence, not merely HPV detection.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "Field-valid causal perturbation means: Endogenous genetic manipulation in autochthonous models; Patient-derived system perturbation with matched rescue AND in vivo confirmation; Clonal tracking demonstrating persistence of dependency through selection pressure.", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "Conditional HPV16-E7 repression in an autochthonous cervical model [11], with resident viral-gene loss of function in primary human tumour cells [13].", "gamma_hard_rules_triggered": [ "Sphere formation alone — not triggered.", "Marker enrichment alone — not triggered.", "Xenograft tumor-initiation without lineage-resolved endogenous evidence — not triggered.", "In vitro-only mechanistic studies, however elegant — not triggered for the scored convergent set; SC3 includes an autochthonous conditional in-vivo model, while the in-vitro rows are not used alone." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Repression regressed high-grade dysplasia and established tumours in vivo; cell studies add specificity but do not define the ceiling alone.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "Field-valid equivalents in this domain: cohort dose-response across independent populations, withdrawal-and-rechallenge at population scale (exposure cessation followed by incidence decline), germline or somatic genetic natural experiments, and prophylactic or therapeutic perturbation with an incidence or survival endpoint.", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "FUTURE II and PATRICIA randomized prophylaxis [7,8], randomized HPV screening [21], and national invasive-cancer programmes [9,10,23].", "gamma_hard_rules_triggered": [ "Sphere formation alone — not triggered.", "Marker enrichment alone — not triggered.", "Xenograft tumor-initiation without lineage-resolved endogenous evidence — not triggered.", "In vitro-only mechanistic studies, however elegant — not triggered for the scored convergent set; SC3 includes an autochthonous conditional in-vivo model, while the in-vitro rows are not used alone." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Interventions change CIN3/AIS and invasive carcinoma, with the largest effect when vaccination precedes likely infection.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC5", "field_valid_perturbation_quote": "Field-valid equivalents in this domain: cohort dose-response across independent populations, withdrawal-and-rechallenge at population scale (exposure cessation followed by incidence decline), germline or somatic genetic natural experiments, and prophylactic or therapeutic perturbation with an incidence or survival endpoint.", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "Morphology-first IECC development and validation [16,20], broad-assay retesting [1,18], and true HPV-independent SCC series [17,24,25].", "gamma_hard_rules_triggered": [ "Sphere formation alone — not triggered.", "Marker enrichment alone — not triggered.", "Xenograft tumor-initiation without lineage-resolved endogenous evidence — not triggered.", "In vitro-only mechanistic studies, however elegant — not triggered for the scored convergent set; SC3 includes an autochthonous conditional in-vivo model, while the in-vitro rows are not used alone." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "The boundary is mapped with positive and negative tumour classes; it is not inferred from marker enrichment alone.", "ceiling_from_boundary_check": "Δ or higher" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Θ", "requirement_quoted": "Requires that the mechanism explains most of the claimed cancer behavior with only minor exceptions.", "satisfied": "yes", "supporting_evidence": [ "Repeated same-type persistence [3,4]", "long-term baseline risk [5]", "type-specific clearance/progression map [22]" ], "what_would_cross_it": "Already crossed for temporality and persistence as the high-risk exposure pattern." }, { "subclaim_id": "SC2", "threshold": "Θ", "requirement_quoted": "Requires that the mechanism explains most of the claimed cancer behavior with only minor exceptions.", "satisfied": "yes", "supporting_evidence": [ "Near-universal attribution after quality control [1,2,6]", "prevention [7-10,23]", "morphology-first boundary [16,20]", "explicit rare exceptions [17,24,25]" ], "what_would_cross_it": "Already crossed for the common independently specified histologies, with rare exceptions retained rather than deleted." }, { "subclaim_id": "SC2", "threshold": "Ω", "requirement_quoted": "Requires necessity and sufficiency across the claimed cancer context, not just one engineered system.", "satisfied": "no", "supporting_evidence": [ "Most infections clear and do not cause cancer [22].", "True HPV-independent cervical SCC exists [17,24,25].", "Several glandular cervical tumour classes are HPV-independent [15,16,20]." ], "what_would_cross_it": "Ω cannot be crossed by the submitted biology: carcinogenic HPV is not sufficient, and modern pathology supplies reproducible HPV-independent counterexamples outside the common pathway." }, { "subclaim_id": "SC3", "threshold": "Η", "requirement_quoted": "Requires: Strong endogenous evidence; Therapeutic or mechanistic consequence; Reproducibility across disease settings within the claimed scope.", "satisfied": "yes", "supporting_evidence": [ "Conditional in-vivo E7 repression [11]", "resident E6/E7 repression [12]", "primary human tumour cells [13]", "genotype-specific CRISPR [14]" ], "what_would_cross_it": "Already crossed within the stated model and primary-cell maintenance scope." }, { "subclaim_id": "SC3", "threshold": "Θ", "requirement_quoted": "Requires that the mechanism explains most of the claimed cancer behavior with only minor exceptions.", "satisfied": "no", "supporting_evidence": [ "No broad human trial has selectively extinguished E6/E7 and established tumour regression across genotypes.", "HPV-undetected or transcriptionally inactive tumours remain heterogeneous [18,19]." ], "what_would_cross_it": "Replicated selective E6/E7-directed human tumour regression with target-engagement mediation, resistant-lesion analysis, and genotype breadth." }, { "subclaim_id": "SC4", "threshold": "Θ", "requirement_quoted": "Requires that the mechanism explains most of the claimed cancer behavior with only minor exceptions.", "satisfied": "yes", "supporting_evidence": [ "Two randomized prophylactic platforms [7,8]", "Swedish invasive-cancer incidence [9]", "England age-at-offer gradient and durability [10,23]", "randomized HPV screening [21]" ], "what_would_cross_it": "Already crossed for prevention before exposure and interruption of the precursor pathway." }, { "subclaim_id": "SC5", "threshold": "Η", "requirement_quoted": "Requires: Strong endogenous evidence; Therapeutic or mechanistic consequence; Reproducibility across disease settings within the claimed scope.", "satisfied": "yes", "supporting_evidence": [ "IECC development and validation [16,20]", "technical false-negative reassessment [1,18]", "genomics [15,19]", "HPVI SCC replication [17,24,25]" ], "what_would_cross_it": "Already crossed for mapped glandular and squamous boundaries." }, { "subclaim_id": "SC5", "threshold": "Θ", "requirement_quoted": "Requires that the mechanism explains most of the claimed cancer behavior with only minor exceptions.", "satisfied": "no", "supporting_evidence": [ "HPV-associated and HPV-independent SCC have substantial morphologic overlap [17,24].", "The diagnosis remains assay-dependent in a small residual set [18,19]." ], "what_would_cross_it": "A prospectively validated, outcome-independent classifier that separates squamous pathways before HPV-result review and resolves broad-assay discordance." } ], "generalization_check": { "generalization_tested": "yes", "context_boundary_mapped": "yes", "internal_negative_controls": [ "Cleared or repeatedly HPV-negative women in prospective cohorts [4,22]", "Morphology-defined gastric-type, clear-cell, mesonephric, and rare endometrioid adenocarcinomas [16,20]", "HPV-independent/p16-negative cervical SCC [17,24,25]", "HPV-negative cervical cancer cell controls in E6/E7 perturbation studies [12,13]", "Pre-existing infection in vaccine intention-to-treat analyses [7,8]" ], "note": "The common HPV-driven pathway generalizes across geography, genotype, squamous and usual glandular histology, and prevention programmes. The boundary is mapped rather than hidden, and rare HPV-independent tumours remain genuine negative controls." }, "falsification_patterns_met": [], "pitfalls_flagged": [ { "subclaim_id": "SC2", "pitfall": "22. Scope fitted to the result", "where": "Defining 'HPV-associated' solely by a positive tumour HPV result makes necessity circular. The gradeable restatement fixes anatomy and common histology before HPV-result review and counts discordances." }, { "subclaim_id": "SC2", "pitfall": "21. A universal cap re-applied to a convergent evidence set", "where": "Case-control association is not allowed to cap the prospective, preventive, mechanistic, and pathology-boundary convergence." }, { "subclaim_id": "SC2", "pitfall": "7. Selective generalization", "where": "The result is not generalized to gastric-type, clear-cell, mesonephric, endometrioid, or verified HPV-independent squamous carcinoma." }, { "subclaim_id": "SC3", "pitfall": "4. In vitro reconstitution treated as demonstration of endogenous function", "where": "Cell-line and primary-cell E6/E7 studies support specificity but do not alone establish human tumour-wide maintenance; the in-vivo conditional model is separate." }, { "subclaim_id": "SC4", "pitfall": "13. Therapeutic effect misread as mechanistic proof", "where": "Vaccination prevents exposure and screening interrupts the precursor pathway; neither alone proves every molecular step or sufficiency." }, { "subclaim_id": "overall", "pitfall": "18. Causal-evidence tallies that do not survive an audit", "where": "Two vaccine RCTs are one prophylactic-modality line, the two England reports are one programme, and three E6/E7 cell studies are not three independent human causal lines." }, { "subclaim_id": "overall", "pitfall": "10. Mechanism conflation", "where": "Etiologic necessity, persistence, continued tumour maintenance, preventive reversibility, and histotype boundary are scored separately." } ], "causal_tally_audit": { "tally_claimed_by_document": 0, "tally_after_audit": 8, "items_rejected": [ "FUTURE II and PATRICIA are independent trials and products but one prophylactic-vaccine modality line for causal-mechanism independence.", "The 2021 and 2025 England reports are one national-programme line with overlapping birth cohorts.", "Kjaer, Chen, Portland Kaiser, and NCI-KPNC are separate prospective cohorts but share repeated HPV testing and screening-related limitations; they form one temporality/persistence line.", "Goodwin, DeFilippis, and Kennedy are distinct experiments but share cell-system failure modes; the conditional mouse experiment supplies the in-vivo maintenance line.", "IECC development and validation are separate cohorts but one morphology-first classification paradigm.", "The 2023 and 2025 HPV-independent SCC reports partly share investigators and selected cases; they establish replication and characterization, not three independent incidence lines.", "TCGA and HPV-undetected genomic papers are cross-sectional tumour profiles, not intervention lines." ] }, "steelman": { "case_one_rung_higher": "The strongest Ω case is that prospective persistence, near-universal multi-assay tumour detection, type-specific vaccination, invasive-cancer incidence declines, and E6/E7 dependency jointly make persistent carcinogenic HPV as close to a necessary human carcinogen as observational biology permits.", "case_one_rung_lower": "The strongest Η case is that the key noun phrase is circular, true HPV-independent squamous and glandular cancers exist, a few morphology-defined common tumours remain HPV-negative, vaccine RCTs primarily used precursor endpoints, and no human experiment establishes infection-level sufficiency or universal E6/E7 dependence.", "which_rejected": "Ω is rejected because its canonical threshold requires both necessity and sufficiency, while most infections clear and true HPV-independent cervical tumours exist. Η is rejected for the corrected etiologic claim because prospective temporality, virus-specific prevention, invasive-cancer natural experiments, tumour attribution, and mechanistic loss of function predict the common pathway with only minor mapped exceptions.", "blocking_cap_threshold_or_missing_experiment": "The Ω blocker is structural rather than a missing sample size: carcinogenic HPV infection is not sufficient for cervical carcinoma, and rare independently confirmed HPV-independent tumours defeat exception-free necessity across all cervical carcinoma." }, "final_score": { "hsef_level": "Θ", "hsef_descriptor": "High predictive accuracy, minimal unresolved exceptions", "confidence": "High", "confidence_rationale": "The core direction is replicated across prospective cohorts, two prophylactic vaccine platforms, national invasive-cancer programmes, randomized screening, multi-target tumour assays, morphology-first pathology, genomics, and E6/E7 loss-of-function systems. Confidence is High in the near-necessity of persistent carcinogenic HPV for the common pathway and lower only for exception-free wording and continued human tumour dependence.", "rests_on_non_peer_reviewed_work": false, "rationale": "Persistent carcinogenic HPV is the primary upstream cause of nearly all common squamous and usual-type cervical carcinomas, and preventing infection changes high-grade and invasive disease as predicted. The claim stops at Θ because 'HPV-associated' is circular unless independently operationalized, most infections are not sufficient, and rare HPV-independent squamous and glandular cervical carcinomas are real." }, "role_of_mechanism": { "classification": "primary driver", "derivation_step_matched": "3", "derivation": "Preventing acquisition substantially prevents the phenotype, persistent E6/E7 engagement initiates the transforming pathway, and the persistent viral exposure is rate-limiting for the common HPV-associated route. Host and environmental cofactors modify progression but do not make the virus a mere passenger in that pathway.", "tournament_used_as_tiebreaker": false, "note": "Primary-driver status applies to the common HPV-associated pathway, not to verified HPV-independent cervical carcinomas and not as a claim that infection alone is sufficient." }, "extended_scoring_MSD": { "momentum": { "value": "Mechanistic only", "artifact": "NCI-2024-09378 / NCT05639972 is an active phase I E7 TCR-T induction trial in locoregionally advanced HPV16-associated cancers, with tumour response and disease-free survival among its outcomes.", "justification": "The trial directly probes E7 as a human therapeutic target and could strengthen SC3, but its multi-component single-arm design cannot establish infection sufficiency or move the overall Θ claim to Ω." }, "stability": { "value": "Stable", "trigger": "NCT05639972 could raise confidence in continued human E7 dependence if target-engaged responses are replicated, while larger prospective HPV-independent SCC series could refine the exception frequency; neither can supply HPV sufficiency.", "justification": "The core grade rests on mature, orthogonal evidence. New work can sharpen maintenance and boundary estimates but is unlikely to change the overall rung soon." }, "divergence": { "implied_level": "Θ", "implied_level_basis": "The scientific phrase 'necessary cause' is generally used for an overwhelmingly attributable but not sufficient infectious component cause, implying a near-top causal claim with mapped exceptions rather than Ω's necessity-plus-sufficiency standard.", "assessed_level": "Θ", "gap_in_rungs": 0, "value": "Aligned", "justification": "Field framing implies Θ and the assessed causal model is Θ, so the rung gap is 0. The wording becomes overstated only when read as an exception-free theorem or as applying to all cervical carcinomas." }, "calibration_note": "M/S/D do not modify HSEF level or confidence. Momentum is tied to a named current trial, stability to named upward and downward triggers, and divergence to explicit rung arithmetic." }, "change_record": { "applies": false, "prior_level": "not supplied", "prior_confidence": "not supplied", "prior_source": "No prior HPV scorecard artifact was supplied for revision in this request.", "derived_before_consulting_prior": true, "new_level": "Θ", "direction": "newly assigned", "what_moved_it": "Fresh preregistered decomposition and current evidence through the review date, including 2025 HPV-independent SCC series.", "divergence_from_other_reviewers": "Earlier conversation criticized circular scope qualifiers, missing independent lines, subclaim typing, and unsupported Θ assignments. This review applies those corrections prospectively; no sealed expected grade was supplied." }, "proposed_decisive_experiments": [ { "name": "Prospective outcome-independent cervical pathway classifier", "experiment": "Enroll consecutive primary cervical carcinomas and freeze the anatomic and histomorphologic class before any HPV, p16, or genomic result; then apply orthogonal DNA, RNA, serologic, and integration assays with blinded central review.", "readout": "Fraction of each predeclared histologic class with type-concordant causal HPV evidence, plus a molecularly coherent HPV-independent trajectory in discordant cases.", "critical_control": "Endometrial or metastatic mimics, degraded archival blocks, HPV-independent glandular types, and synthetic low-copy controls for each assay target.", "falsifying_result": "A reproducible, nontrivial fraction of predeclared common-pathway tumours lacks all causal HPV evidence despite adequate tissue and instead shows an independent precursor and genomic route.", "supporting_result": "Nearly all common-pathway tumours retain type-concordant viral evidence, while negatives cluster prospectively in distinct HPV-independent classes." }, { "name": "Human E7-dependence mediation trial", "experiment": "In a genotype- and HLA-defined trial such as NCT05639972, quantify E7 target engagement, tumour-cell killing, viral transcript change, resistant clones, and radiographic/pathologic response before standard therapy.", "readout": "Within-patient tumour regression mediated by selective loss of E7-expressing clones, with disease-free follow-up.", "critical_control": "Pretreatment and on-treatment biopsies, HLA-loss and antigen-loss analysis, independent immune activation markers, and non-HPV tumour controls where ethically feasible.", "falsifying_result": "Adequate E7 target engagement repeatedly fails to alter tumour viability or selectively spares E7-expressing clones.", "supporting_result": "Replicated tumour regression tracks E7-specific engagement and resistance arises through antigen or presentation loss." }, { "name": "Longitudinal lineage test of hit-and-run HPV", "experiment": "Use archived preinvasive lesions, primary tumours, and recurrences from the same patients with integration-site sequencing and viral-host junction lineage tracing.", "readout": "Direct evidence of a shared clone that contained causal HPV early and later lost all viral sequence and oncogene expression.", "critical_control": "Independent tumour origin, contamination, assay sensitivity, and sampling of spatially heterogeneous viral copies.", "falsifying_result": "All well-sampled HPV-undetected tumours lack an earlier type-concordant viral lineage or resolve into technical/histotype explanations.", "supporting_result": "Multiple independent tumours show an unambiguous viral integration lineage followed by complete viral loss while retaining clonal ancestry." } ], "knowledge_gaps": [ { "name": "Noncircular squamous classification", "statement": "No morphology-only rule separates HPV-associated from HPV-independent cervical SCC with the accuracy achieved for endocervical adenocarcinoma.", "relevance": "This is the main scope-falsifiability weakness in the submitted wording." }, { "name": "True HPVI SCC prevalence", "statement": "Reported fractions depend on assay breadth, p16 criteria, tissue quality, age, referral pattern, and whether selected negative cases or consecutive tumours are sampled.", "relevance": "Affects how literally 'necessary' can be used and the size of the mapped exception set." }, { "name": "Human tumour maintenance", "statement": "Selective E6/E7 ablation has not yet established broad, mediated tumour regression across human cervical cancer genotypes and resistance states.", "relevance": "This is the direct blocker to Θ for SC3, not to etiologic necessity." }, { "name": "Hit-and-run frequency", "statement": "A causal lineage from earlier HPV-positive precursor to fully HPV-negative descendant has not been demonstrated at useful frequency with integration-site lineage tracing.", "relevance": "Would reclassify some apparent independent tumours and alter the exception accounting." }, { "name": "Rare genotype attribution", "statement": "The causal status of very rare, nominally probable, or low-risk HPV genotypes in cervical carcinoma remains difficult to distinguish from coinfection and assay-panel gaps.", "relevance": "Defines whether 'high-risk genotype' needs a fixed or evolving genotype list." } ], "review_metadata": { "review_date": "2026-09-29", "reviewer": "OpenAI Codex using HSEF v5.4", "evidence_base_note": "Primary prospective, tumour-attribution, randomized prophylaxis, population-incidence, screening, pathology, genomics, and viral-oncogene perturbation evidence through 2026-09-29. Full text was read wherever accessible and abstract-only rows are labeled. The attached packet (SHA256 7E097D3D50D2068F68BDB1CD022DF4A045DAC46A9F25E51262EC7568E9DB11EB) was treated as methodology, not scientific evidence.", "literature_tools_available": true, "literature_tools_note": "PubMed identity/status records, PubMed Central full text, ClinicalTrials.gov/NCI registry material, and primary publisher abstracts were used. Scite was unavailable by user report, so citation-context counts were not fabricated.", "skill_version": "5.4", "validator_run": "pass", "validator_warnings_addressed": "Validator 2.4 was run after explicit circularity, scope, subclaim, access-depth, correction, aggregation, independence, upper-ladder, claim-to-source, and ZIP-integrity checks; see the companion validation report. Cross-model red-team pass (2026-09-30) re-validated with validator 2.2; see the companion red-team logs and validation report.", "red_team_note": "Cross-model red team (Claude, Anthropic) on 2026-09-30 re-resolved all references by identifier, re-confirmed headline numeric claims against primary sources, added one verified reference (26; Palmer 2024, Scotland), added a rubric-routing completeness note, and made no score change. Audit trail: redteam/REDTEAM_REPORT.md; redteam/SYNTHESIS_CHANGE_LOG.md.", "consensus_consistency_audit": "2026-10-09; supplementary provenance/source reconciliation; original grading retained; prior grades visible." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": false, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "No independently authored sealed calibration target was supplied.", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "Standalone evaluation; no sealed target was supplied to a generating session that could not read it." }, "upper_ladder_check": { "final_level_below_zeta": false, "equivalents_considered": [ { "kind": "cohort dose-response across independent populations", "available": true, "why_not_sufficient": "It directly supports SC1 and SC2 and is interpreted with screening and endpoint limits." }, { "kind": "population-scale exposure prevention followed by incidence decline", "available": true, "why_not_sufficient": "National vaccine programmes supply invasive-cancer evidence and are grouped by programme rather than report." }, { "kind": "prophylactic perturbation with an incidence endpoint", "available": true, "why_not_sufficient": "Two randomized vaccine platforms prevent high-grade disease; long-latency invasive cancer is supplied by population programmes." }, { "kind": "therapeutic or mechanistic perturbation", "available": true, "why_not_sufficient": "Conditional E7 repression and resident E6/E7 loss of function support maintenance but do not establish infection sufficiency." } ], "convergence_present": true, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 26, "claims_total": 27, "claims_verified": 27, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 26, "generated_by": "HSEF v5.4 evidence-gated review workflow", "gate_passed": true }, "claims": [ { "id": "C1", "text": "After multi-target PCR reanalysis and exclusion of qualitatively inadequate specimens, Walboomers et al. estimated HPV prevalence at 99.7% in cervical carcinomas; only 2 of 34 adequate formerly negative specimens remained negative by all PCR tests.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "PubMed abstract, methods summary, results, and bibliographic record", "verified_on": "2026-09-29", "note": "The study predates modern recognition of several HPV-independent cervical histotypes; it demonstrates how specimen quality and assay target choice create false negatives, not exception-free universality." }, { "id": "C2", "text": "Across 11 case-control studies, HPV DNA was detected in 90.7% of 1,918 squamous cervical cancers and 13.4% of 1,928 controls; the pooled odds ratio using GP5+/6+ testing was 158.2, and 15 genotypes were classified as high risk.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "PubMed abstract and bibliographic record", "verified_on": "2026-09-29", "note": "Large multi-country association and genotype classification; retrospective tumour detection cannot alone prove persistence or necessity." }, { "id": "C3", "text": "In 10,758 initially cytologically normal young women, repeat detection of the same high-risk HPV type was associated with an odds ratio of 813.0 for a later high-grade squamous lesion compared with HPV negativity.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "complete PMC full text, cohort methods, tables, and discussion", "verified_on": "2026-09-29", "note": "A PubMed-linked erratum is flagged in the ledger. The endpoint is high-grade lesion, not invasive cancer." }, { "id": "C4", "text": "In a 16-year cohort of 10,123 initially cytologically normal women, type-specific persistence of a carcinogenic HPV was associated with HR 75.4 versus repeated negativity; cumulative carcinoma risk was 12.4% after persistence and 0.14% after repeated negativity.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "complete PMC full text, methods, results, figures, and limitations", "verified_on": "2026-09-29", "note": "The outcome combined carcinoma in situ and invasive carcinoma; HPV was not retyped at cancer diagnosis in every participant." }, { "id": "C5", "text": "In the approximately 20,000-woman Portland Kaiser cohort, 47 invasive cancers and 156 CIN3 cases occurred over up to 18 years; a positive baseline HPV test had HR 8.5 for CIN3 or cancer, and a negative test carried a 0.7% cumulative probability.", "carries_number": true, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "complete PMC full text, results, figures, and limitations", "verified_on": "2026-09-29", "note": "The combined endpoint and passive cytology follow-up limit direct inference about invasive cancer alone; a PubMed-listed erratum is flagged." }, { "id": "C6", "text": "In 10,575 invasive cervical cancers from 38 countries, 8,977 (85%) were HPV-DNA positive; eight genotypes accounted for 91% of HPV-positive cases, and HPV16/18 accounted for 71%.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "PubMed abstract, methods summary, and bibliographic record", "verified_on": "2026-09-29", "note": "The 85% detection rate is lower than sensitive reanalysis estimates and is affected by specimen, histotype, and assay heterogeneity." }, { "id": "C7", "text": "In the 12,167-participant FUTURE II randomized trial, quadrivalent vaccination prevented the HPV16/18-related CIN2/3, adenocarcinoma-in-situ, or cancer composite with 98% efficacy in the per-protocol susceptible population and 44% efficacy in the intention-to-treat population; efficacy against all-type high-grade lesions was 17%.", "carries_number": true, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "PubMed abstract, randomized design, endpoint definition, and bibliographic record", "verified_on": "2026-09-29", "note": "The short trial primarily tested high-grade precursors rather than invasive cancer and illustrates that prophylaxis cannot treat pre-existing infection." }, { "id": "C8", "text": "At four years in PATRICIA, vaccine efficacy in HPV-naive participants was 100% against HPV16/18-associated CIN3+ and 93.2% against CIN3+ irrespective of HPV type; corresponding total-cohort efficacy against all CIN3+ was 45.6%.", "carries_number": true, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "PubMed abstract, population definitions, endpoints, and bibliographic record", "verified_on": "2026-09-29", "note": "A PubMed-listed erratum is flagged. Cross-protection and lesion attribution mean all-type efficacy is supportive but not a one-genotype-one-lesion proof." }, { "id": "C9", "text": "In Sweden, 19 invasive cervical cancers occurred among vaccinated women and 538 among unvaccinated women; the adjusted incidence-rate ratio was 0.37 overall and 0.12 for vaccination before age 17.", "carries_number": true, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "PubMed abstract, adjusted analysis, and bibliographic record", "verified_on": "2026-09-29", "note": "A national observational study with adjustment, not individual randomization; early vaccination produces the larger effect predicted by prevention before exposure." }, { "id": "C10", "text": "England's national programme was associated with 87% lower cervical-cancer incidence and 97% lower CIN3 incidence in women offered vaccination at ages 12-13, with an estimated 448 fewer cancers and 17,235 fewer CIN3 cases through June 2019.", "carries_number": true, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "PubMed abstract, cohort definitions, estimates, and bibliographic record", "verified_on": "2026-09-29", "note": "The age-at-offer gradient and invasive endpoint are strong natural-experiment evidence; screening and secular changes remain residual confounders." }, { "id": "C11", "text": "In a conditional HPV16-E7 cervical-cancer mouse model, doxycycline-mediated E7 repression caused regression of high-grade dysplasia and established cervical tumours.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "complete PMC full text, conditional-model design, histology, results, and discussion", "verified_on": "2026-09-29", "note": "This is an autochthonous conditional oncogene model with estrogen exposure, not a natural human infection or human therapeutic ablation." }, { "id": "C12", "text": "Repression of resident HPV E6/E7 in cervical carcinoma cell lines caused rapid senescence, with viral-gene and HPV-negative controls supporting specificity.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "complete PMC full text, intervention, controls, and rescue discussion", "verified_on": "2026-09-29", "note": "Strong molecular dependency within adapted cell lines; it cannot alone establish tumour-wide human maintenance dependence." }, { "id": "C13", "text": "In low-passage primary human cervical carcinoma cells, E6/E7 repression induced senescence and had little effect in HPV-negative cervical cancer cells.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "complete PMC full text, primary-cell methods, results, and controls", "verified_on": "2026-09-29", "note": "Patient-derived cells reduce cell-line drift but remain ex vivo and lack matched in-vivo rescue." }, { "id": "C14", "text": "CRISPR cleavage of HPV16 or HPV18 E6/E7 in cervical carcinoma cells restored p53 or Rb pathway activity and produced cell-cycle arrest or cell death in genotype-matched systems.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "complete PMC full text, targeting design, controls, results, and limitations", "verified_on": "2026-09-29", "note": "Genotype-specific loss of function is mechanistically informative but remains an in-vitro intervention." }, { "id": "C15", "text": "In the TCGA core cohort, 169 of 178 cervical tumours (95%) were HPV-positive; seven of nine HPV-negative tumours were endometrial-like and carried distinct KRAS, ARID1A, and PTEN alterations.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "complete PMC full text, cohort table, viral analysis, and genomic subgroup results", "verified_on": "2026-09-29", "note": "Supports histotype mixture and a molecularly distinct HPV-independent group; TCGA selection is not population incidence sampling." }, { "id": "C16", "text": "In 409 endocervical adenocarcinomas classified by morphology before HPV testing, 95% of adequately processed usual-type tumours were HPV-positive, whereas only 3% of non-HPV-associated morphologic types were HPV-positive.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "complete PMC full text, morphology criteria, assay methods, tables, and discussion", "verified_on": "2026-09-29", "note": "A key noncircular boundary study: morphology was assigned independently of HPV result, though some usual-type outliers remained HPV-negative." }, { "id": "C17", "text": "Among 447 evaluable tumours from a 670-case squamous-carcinoma cohort, 10 were HPV-independent, 435 HPV-associated, and two equivocal, yielding a 2% HPV-independent fraction in the tested set.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "complete PMC full text, centralized review, HPV mRNA ISH, p16 criteria, and results", "verified_on": "2026-09-29", "note": "This is direct counterevidence to an all-cervical-SCC necessity claim and a mapped negative control for the scoped HPV-associated pathway." }, { "id": "C18", "text": "In a Swedish cervical-cancer cohort, retesting with L1 and E6/E7 assays plus pathology review reduced the HPV-negative fraction from 14% to 7%; remaining negatives were enriched for older age, adenocarcinoma, and long specimen storage.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "complete PMC full text, assay workflow, pathology review, results, and limitations", "verified_on": "2026-09-29", "note": "Shows both technical false negativity and a residual biologically heterogeneous HPV-undetected group." }, { "id": "C19", "text": "Genomic comparison of 35 HPV-undetected with 430 HPV-positive cervical carcinomas found distinct molecular features and worse outcomes in the HPV-undetected group.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 19 ], "verification": "verified", "verified_against": "complete PMC full text, cohort construction, genomic results, survival analyses, and caveats", "verified_on": "2026-09-29", "note": "Undetected is not synonymous with proven HPV-independent; the group can mix true independent tumours, assay failure, and biologically inactive virus." }, { "id": "C20", "text": "In an independent 111-case endocervical adenocarcinoma series, p16 and HPV RNA-ISH were concordant in 108 cases (97%), and morphology-versus-HPV agreement improved from 103 of 111 to 107 of 111 after review.", "carries_number": true, "load_bearing_for": [ "SC5" ], "source_ns": [ 20 ], "verification": "verified", "verified_against": "complete PMC full text, tables, discordant-case review, and discussion", "verified_on": "2026-09-29", "note": "External validation supports a morphology-first boundary while preserving discordant cases rather than post hoc deleting them." }, { "id": "C21", "text": "Across four European randomized screening trials with 176,464 women and 107 invasive cancers, HPV-based screening reduced invasive cervical cancer overall (RR 0.60) and after 2.5 years (RR 0.45) compared with cytology-based screening.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 21 ], "verification": "verified", "verified_against": "PubMed abstract, pooled randomized design, endpoint counts, and bibliographic record", "verified_on": "2026-09-29", "note": "Screening plus treatment removes detected precursor disease; it is a pathway intervention rather than a direct test that infection alone is sufficient. A PubMed-linked erratum is flagged." }, { "id": "C22", "text": "Among 14,158 type-specific infections in 11,573 HPV-positive women, approximately 80% cleared by three years; HPV16 carried a seven-year CIN3+ risk of 22%, with materially lower risks for several other carcinogenic types.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC5" ], "source_ns": [ 22 ], "verification": "verified", "verified_against": "complete PMC full text, natural-history definitions, type-stratified results, and discussion", "verified_on": "2026-09-29", "note": "Directly shows that infection, even when persistent for a time, is not sufficient and that genotype matters." }, { "id": "C23", "text": "The England follow-up through 2020 included 53.4 million woman-years, 5,558 cervical cancers, and 164,682 CIN3 cases in women aged 20-29.99; trends in routinely vaccinated cohorts were consistent with an 80% decrease in cervical neoplasia.", "carries_number": true, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 23 ], "verification": "verified", "verified_against": "complete PMC full text, registry methods, trend analyses, figures, and limitations", "verified_on": "2026-09-29", "note": "This extends the same national programme as source 10 and is one independence line, not a second intervention." }, { "id": "C24", "text": "A 2025 multicentre series assembled 89 previously HPV-negative cervical squamous carcinomas; 49 were HPV-negative/p16-negative and classified as true HPV-independent SCC, whereas 40 HPV-negative/p16-positive or untested cases were excluded as equivocal.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 24 ], "verification": "verified", "verified_against": "PubMed abstract, eligibility criteria, subgroup definitions, and bibliographic record", "verified_on": "2026-09-29", "note": "Case-assembled series establishes existence and phenotype, not the population prevalence of HPV-independent SCC." }, { "id": "C25", "text": "A 2025 full-text molecular series described six p16-negative, high-risk-HPV-negative cervical squamous carcinomas with clinicopathologic and genomic features including TP53, PIK3CA, CTNNB1, TERT-promoter, or ERBB2 alterations.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 25 ], "verification": "verified", "verified_against": "complete PMC full text, case methods, HPV assay, pathology, genomic results, and discussion", "verified_on": "2026-09-29", "note": "Small descriptive series but orthogonal molecular support for a rare HPV-independent squamous pathway." }, { "id": "C26", "text": "The total evidence supports type-specific persistent carcinogenic HPV as the primary upstream cause of nearly all squamous and usual-type cervical carcinomas, but not as a sufficient exposure and not as a logically exception-free necessity across all cervical carcinomas.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3", "SC4", "SC5" ], "source_ns": [ 1, 4, 7, 8, 9, 11, 15, 16, 17, 18, 20, 22, 23, 24, 25 ], "verification": "verified", "verified_against": "cross-source synthesis after claim-level verification and independence audit", "verified_on": "2026-09-29", "note": "This is the adjudicative synthesis. It keeps necessity, sufficiency, continued dependence, and tumour-class boundaries separate." }, { "id": "C27", "text": "In Scotland's bivalent HPV vaccination programme, no invasive cervical cancers were recorded among women immunized at age 12-13 regardless of dose number; women given three doses at age 14-22 had an incidence of 3.2 per 100,000 person-years versus 8.4 among all unvaccinated women.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 26 ], "verification": "verified", "verified_against": "PubMed abstract, observational-cohort design, dose/age strata, incidence estimates, and bibliographic record", "verified_on": "2026-09-30", "note": "Added by the cross-model red team as an independent national-population readout supporting SC4. A registry-linkage observational study, not individual randomization; strengthens the invasive-cancer prevention line without supplying infection sufficiency." } ], "citation_ledger": [ { "n": 1, "citation": "Walboomers et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.. The Journal of pathology. 1999.", "tier": "A", "kind": "primary", "pmid": "10451482", "pmcid": "", "doi": "10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F", "url": "https://pubmed.ncbi.nlm.nih.gov/10451482/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "WORLDWIDE-CERVIX-REANALYSIS-1999", "access_depth": "abstract_metadata", "access_note": "PubMed abstract, study design, endpoints, bibliographic identity, and correction/status metadata were read; no full-text-only claim is attributed to this source.", "carries_claims": [ "C1", "C26" ] }, { "n": 2, "citation": "Muñoz et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer.. The New England journal of medicine. 2003.", "tier": "A", "kind": "primary", "pmid": "12571259", "pmcid": "", "doi": "10.1056/NEJMoa021641", "url": "https://pubmed.ncbi.nlm.nih.gov/12571259/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "IARC-11-CASECONTROL-POOLED", "access_depth": "abstract_metadata", "access_note": "PubMed abstract, study design, endpoints, bibliographic identity, and correction/status metadata were read; no full-text-only claim is attributed to this source.", "carries_claims": [ "C2" ] }, { "n": 3, "citation": "Kjaer et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study.. BMJ (Clinical research ed.). 2002.", "tier": "A", "kind": "primary", "pmid": "12228133", "pmcid": "PMC124551", "doi": "10.1136/bmj.325.7364.572", "url": "https://pubmed.ncbi.nlm.nih.gov/12228133/", "status_flags": [ "erratum: BMJ. 2016;353:i2820; PMID 27193125" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "COPENHAGEN-YOUNG-WOMEN-COHORT", "access_depth": "full_text_complete", "access_note": "Complete PubMed Central full text was read, including methods, results, limitations, and relevant tables or figures.", "carries_claims": [ "C3" ] }, { "n": 4, "citation": "Chen et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer.. Journal of the National Cancer Institute. 2011.", "tier": "A", "kind": "primary", "pmid": "21900119", "pmcid": "PMC3176778", "doi": "10.1093/jnci/djr283", "url": "https://pubmed.ncbi.nlm.nih.gov/21900119/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "CBCSP-TAIWAN-16Y", "access_depth": "full_text_complete", "access_note": "Complete PubMed Central full text was read, including methods, results, limitations, and relevant tables or figures.", "carries_claims": [ "C4", "C26" ] }, { "n": 5, "citation": "Schiffman et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2011.", "tier": "A", "kind": "primary", "pmid": "21602310", "pmcid": "PMC3156084", "doi": "10.1158/1055-9965.EPI-11-0206", "url": "https://pubmed.ncbi.nlm.nih.gov/21602310/", "status_flags": [ "erratum: PubMed lists ErratumIn; identifier was unavailable in the retrieved parent record" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "PORTLAND-KAISER-COHORT", "access_depth": "full_text_complete", "access_note": "Complete PubMed Central full text was read, including methods, results, limitations, and relevant tables or figures.", "carries_claims": [ "C5" ] }, { "n": 6, "citation": "de Sanjose et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.. The Lancet. Oncology. 2010.", "tier": "A", "kind": "primary", "pmid": "20952254", "pmcid": "", "doi": "10.1016/S1470-2045(10)70230-8", "url": "https://pubmed.ncbi.nlm.nih.gov/20952254/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "ICO-WORLDWIDE-ICC-GENOTYPE", "access_depth": "abstract_metadata", "access_note": "PubMed abstract, study design, endpoints, bibliographic identity, and correction/status metadata were read; no full-text-only claim is attributed to this source.", "carries_claims": [ "C6" ] }, { "n": 7, "citation": "FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.. The New England journal of medicine. 2007.", "tier": "A", "kind": "rct", "pmid": "17494925", "pmcid": "", "doi": "10.1056/NEJMoa061741", "url": "https://pubmed.ncbi.nlm.nih.gov/17494925/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "FUTURE-II-NCT00092534", "access_depth": "abstract_metadata", "access_note": "PubMed abstract, study design, endpoints, bibliographic identity, and correction/status metadata were read; no full-text-only claim is attributed to this source.", "carries_claims": [ "C7", "C26" ] }, { "n": 8, "citation": "Lehtinen et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.. The Lancet. Oncology. 2012.", "tier": "A", "kind": "rct", "pmid": "22075171", "pmcid": "", "doi": "10.1016/S1470-2045(11)70286-8", "url": "https://pubmed.ncbi.nlm.nih.gov/22075171/", "status_flags": [ "erratum: PubMed lists ErratumIn; identifier was unavailable in the retrieved parent record" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "PATRICIA-NCT00122681", "access_depth": "abstract_metadata", "access_note": "PubMed abstract, study design, endpoints, bibliographic identity, and correction/status metadata were read; no full-text-only claim is attributed to this source.", "carries_claims": [ "C8", "C26" ] }, { "n": 9, "citation": "Lei et al. HPV Vaccination and the Risk of Invasive Cervical Cancer.. The New England journal of medicine. 2020.", "tier": "A", "kind": "primary", "pmid": "32997908", "pmcid": "", "doi": "10.1056/NEJMoa1917338", "url": "https://pubmed.ncbi.nlm.nih.gov/32997908/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "SWEDEN-NATIONAL-HPV-VACCINE", "access_depth": "abstract_metadata", "access_note": "PubMed abstract, study design, endpoints, bibliographic identity, and correction/status metadata were read; no full-text-only claim is attributed to this source.", "carries_claims": [ "C9", "C26" ] }, { "n": 10, "citation": "Falcaro et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.. Lancet (London, England). 2021.", "tier": "A", "kind": "primary", "pmid": "34741816", "pmcid": "", "doi": "10.1016/S0140-6736(21)02178-4", "url": "https://pubmed.ncbi.nlm.nih.gov/34741816/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "ENGLAND-NATIONAL-HPV-PROGRAMME", "access_depth": "abstract_metadata", "access_note": "PubMed abstract, study design, endpoints, bibliographic identity, and correction/status metadata were read; no full-text-only claim is attributed to this source.", "carries_claims": [ "C10" ] }, { "n": 11, "citation": "Jabbar et al. Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene.. Cancer research. 2009.", "tier": "A", "kind": "primary", "pmid": "19435895", "pmcid": "PMC3006677", "doi": "10.1158/0008-5472.CAN-09-0023", "url": "https://pubmed.ncbi.nlm.nih.gov/19435895/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "CONDITIONAL-HPV16-E7-MOUSE", "access_depth": "full_text_complete", "access_note": "Complete PubMed Central full text was read, including methods, results, limitations, and relevant tables or figures.", "carries_claims": [ "C11", "C26" ] }, { "n": 12, "citation": "Goodwin et al. Rapid induction of senescence in human cervical carcinoma cells.. Proceedings of the National Academy of Sciences of the United States of America. 2000.", "tier": "A", "kind": "primary", "pmid": "11005870", "pmcid": "PMC27134", "doi": "10.1073/pnas.97.20.10978", "url": "https://pubmed.ncbi.nlm.nih.gov/11005870/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "E2-REPRESSION-CERVICAL-LINES", "access_depth": "full_text_complete", "access_note": "Complete PubMed Central full text was read, including methods, results, limitations, and relevant tables or figures.", "carries_claims": [ "C12" ] }, { "n": 13, "citation": "Magaldi et al. Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation.. Virology. 2012.", "tier": "A", "kind": "primary", "pmid": "22056390", "pmcid": "PMC3229657", "doi": "10.1016/j.virol.2011.10.012", "url": "https://pubmed.ncbi.nlm.nih.gov/22056390/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "PRIMARY-CERVICAL-CARCINOMA-E6E7", "access_depth": "full_text_complete", "access_note": "Complete PubMed Central full text was read, including methods, results, limitations, and relevant tables or figures.", "carries_claims": [ "C13" ] }, { "n": 14, "citation": "Kennedy et al. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease.. Journal of virology. 2014.", "tier": "A", "kind": "primary", "pmid": "25100830", "pmcid": "PMC4178730", "doi": "10.1128/JVI.01879-14", "url": "https://pubmed.ncbi.nlm.nih.gov/25100830/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "CRISPR-E6E7-CERVICAL-LINES", "access_depth": "full_text_complete", "access_note": "Complete PubMed Central full text was read, including methods, results, limitations, and relevant tables or figures.", "carries_claims": [ "C14" ] }, { "n": 15, "citation": "Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer.. Nature. 2017.", "tier": "A", "kind": "primary", "pmid": "28112728", "pmcid": "PMC5354998", "doi": "10.1038/nature21386", "url": "https://pubmed.ncbi.nlm.nih.gov/28112728/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "TCGA-CESC-2017", "access_depth": "full_text_complete", "access_note": "Complete PubMed Central full text was read, including methods, results, limitations, and relevant tables or figures.", "carries_claims": [ "C15", "C26" ] }, { "n": 16, "citation": "Stolnicu et al. International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix.. The American journal of surgical pathology. 2018.", "tier": "A", "kind": "primary", "pmid": "29135516", "pmcid": "PMC5762258", "doi": "10.1097/PAS.0000000000000986", "url": "https://pubmed.ncbi.nlm.nih.gov/29135516/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "IECC-DEVELOPMENT-409", "access_depth": "full_text_complete", "access_note": "Complete PubMed Central full text was read, including methods, results, limitations, and relevant tables or figures.", "carries_claims": [ "C16", "C26" ] }, { "n": 17, "citation": "Stolnicu et al. Incidence and Clinicopathologic Characteristics of Human Papillomavirus-independent Invasive Squamous Cell Carcinomas of the Cervix: A Morphologic, Immunohistochemical, and Human Papilloma-Virologic Study of 670 Cases.. The American journal of surgical pathology. 2023.", "tier": "A", "kind": "primary", "pmid": "37702216", "pmcid": "PMC10840845", "doi": "10.1097/PAS.0000000000002122", "url": "https://pubmed.ncbi.nlm.nih.gov/37702216/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "ISCCP-670-SCC", "access_depth": "full_text_complete", "access_note": "Complete PubMed Central full text was read, including methods, results, limitations, and relevant tables or figures.", "carries_claims": [ "C17", "C26" ] }, { "n": 18, "citation": "Kaliff et al. HPV-negative Tumors in a Swedish Cohort of Cervical Cancer.. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 2020.", "tier": "A", "kind": "primary", "pmid": "31206367", "pmcid": "PMC7147426", "doi": "10.1097/PGP.0000000000000612", "url": "https://pubmed.ncbi.nlm.nih.gov/31206367/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "SWEDISH-HPV-NEGATIVE-RETEST", "access_depth": "full_text_complete", "access_note": "Complete PubMed Central full text was read, including methods, results, limitations, and relevant tables or figures.", "carries_claims": [ "C18", "C26" ] }, { "n": 19, "citation": "Ruiz et al. Genomic Characterization and Therapeutic Targeting of HPV Undetected Cervical Carcinomas.. Cancers. 2021.", "tier": "A", "kind": "primary", "pmid": "34572780", "pmcid": "PMC8467954", "doi": "10.3390/cancers13184551", "url": "https://pubmed.ncbi.nlm.nih.gov/34572780/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "HPV-UNDETECTED-GENOMIC-COMPARISON", "access_depth": "full_text_complete", "access_note": "Complete PubMed Central full text was read, including methods, results, limitations, and relevant tables or figures.", "carries_claims": [ "C19" ] }, { "n": 20, "citation": "Ren et al. Evaluation of human papillomavirus (HPV) prediction using the International Endocervical Adenocarcinoma Criteria and Classification system, compared to p16 immunohistochemistry and HPV RNA in-situ hybridization.. Journal of pathology and translational medicine. 2020.", "tier": "A", "kind": "primary", "pmid": "32854489", "pmcid": "PMC7674758", "doi": "10.4132/jptm.2020.07.18", "url": "https://pubmed.ncbi.nlm.nih.gov/32854489/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "IECC-VALIDATION-111", "access_depth": "full_text_complete", "access_note": "Complete PubMed Central full text was read, including methods, results, limitations, and relevant tables or figures.", "carries_claims": [ "C20", "C26" ] }, { "n": 21, "citation": "Ronco et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.. Lancet (London, England). 2014.", "tier": "A", "kind": "rct", "pmid": "24192252", "pmcid": "", "doi": "10.1016/S0140-6736(13)62218-7", "url": "https://pubmed.ncbi.nlm.nih.gov/24192252/", "status_flags": [ "erratum: Lancet. 2015;386(10009):2254; PMID 26466047" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "EUROPEAN-HPV-SCREENING-POOLED-RCTS", "access_depth": "abstract_metadata", "access_note": "PubMed abstract, study design, endpoints, bibliographic identity, and correction/status metadata were read; no full-text-only claim is attributed to this source.", "carries_claims": [ "C21" ] }, { "n": 22, "citation": "Demarco et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs.. EClinicalMedicine. 2020.", "tier": "A", "kind": "primary", "pmid": "32510043", "pmcid": "PMC7264956", "doi": "10.1016/j.eclinm.2020.100293", "url": "https://pubmed.ncbi.nlm.nih.gov/32510043/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "NCI-KPNC-PAP-STUDY", "access_depth": "full_text_complete", "access_note": "Complete PubMed Central full text was read, including methods, results, limitations, and relevant tables or figures.", "carries_claims": [ "C22", "C26" ] }, { "n": 23, "citation": "Falcaro et al. Association between HPV vaccination and cervical screening policy changes and cervical cancer incidence and grade-3 cervical intraepithelial neoplasia incidence in England, 2006-2020: a population-based trends analysis.. The Lancet regional health. Europe. 2025.", "tier": "A", "kind": "primary", "pmid": "39759575", "pmcid": "PMC11697118", "doi": "10.1016/j.lanepe.2024.101157", "url": "https://pubmed.ncbi.nlm.nih.gov/39759575/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "ENGLAND-NATIONAL-HPV-PROGRAMME", "access_depth": "full_text_complete", "access_note": "Complete PubMed Central full text was read, including methods, results, limitations, and relevant tables or figures.", "carries_claims": [ "C23", "C26" ] }, { "n": 24, "citation": "Stolnicu et al. Cervical Human Papillomavirus-Independent Squamous Cell Carcinoma: A Clinicopathological Review and Outcomes Analysis Compared With Human Papillomavirus-Associated Squamous Cell Carcinoma. Modern pathology. 2025.", "tier": "A", "kind": "primary", "pmid": "40010435", "pmcid": "", "doi": "10.1016/j.modpat.2025.100742", "url": "https://pubmed.ncbi.nlm.nih.gov/40010435/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "MULTICENTRE-HPVI-SCC-CASE-SERIES", "access_depth": "abstract_metadata", "access_note": "PubMed abstract, study design, endpoints, bibliographic identity, and correction/status metadata were read; no full-text-only claim is attributed to this source.", "carries_claims": [ "C24", "C26" ] }, { "n": 25, "citation": "Kır et al. HPV-independent squamous cell carcinoma of cervix: a clinicopathological, immunohistochemical, and molecular analysis of six cases. Virchows Archiv. 2025.", "tier": "A", "kind": "primary", "pmid": "40347270", "pmcid": "PMC12546508", "doi": "10.1007/s00428-025-04113-6", "url": "https://pubmed.ncbi.nlm.nih.gov/40347270/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-29", "study_id": "ISTANBUL-HPVI-SCC-SIX-CASES", "access_depth": "full_text_complete", "access_note": "Complete PubMed Central full text was read, including methods, results, limitations, and relevant tables or figures.", "carries_claims": [ "C25", "C26" ] }, { "n": 26, "citation": "Palmer et al. Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation. Journal of the National Cancer Institute. 2024.", "tier": "A", "kind": "primary", "pmid": "38247547", "pmcid": "", "doi": "10.1093/jnci/djad263", "url": "https://pubmed.ncbi.nlm.nih.gov/38247547/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "SCOTLAND-NATIONAL-HPV-PROGRAMME", "access_depth": "abstract_metadata", "access_note": "PubMed abstract, observational cohort design, endpoints, dose/age/deprivation strata, and bibliographic identity were read; added by the red team. No full-text-only claim is attributed to this source.", "carries_claims": [ "C27" ] } ], "independence_basis": { "required": true, "lines": [ { "label": "Prospective type-specific persistence", "sources": [ 3, 4, 5, 22 ], "excludes_error": "Establishes exposure before disease and distinguishes persistent from transient or cleared infection; residual shared failures include screening intervention and combined precursor/cancer endpoints." }, { "label": "Worldwide tumour attribution with assay-quality control", "sources": [ 1, 2, 6, 15 ], "excludes_error": "Reduces geographic, genotype, single-PCR-target, and specimen-quality explanations; residual failures are histotype mixture and cross-sectional detection." }, { "label": "Randomized virus-specific prophylaxis", "sources": [ 7, 8 ], "excludes_error": "Breaks behavioral and screening confounding for acquisition-to-high-grade-lesion causality; the trials share the prophylactic L1-VLP mode and short invasive-cancer latency." }, { "label": "Population invasive-cancer prevention", "sources": [ 9, 10, 23, 26 ], "excludes_error": "Extends precursor prevention to invasive cancer across three distinct national populations (Sweden quadrivalent; England bivalent; Scotland bivalent) and shows the predicted early-vaccination gradient; the two England reports are one national programme line, but Sweden and Scotland are separate populations, so no single registry error produces the shared effect." }, { "label": "Randomized HPV-pathway screening intervention", "sources": [ 21 ], "excludes_error": "Shows that identifying and treating HPV-defined precursor risk reduces invasive cancer; it tests pathway interruption rather than infection prevention." }, { "label": "Viral-oncogene loss of function", "sources": [ 11, 12, 13, 14 ], "excludes_error": "Excludes HPV as a passive passenger by showing E6/E7 dependence across an in-vivo conditional model, cell lines, and primary tumour cells; human therapeutic mediation remains unresolved." }, { "label": "Morphology-first pathway classification", "sources": [ 16, 20 ], "excludes_error": "Defines major glandular pathway classes before HPV-result review and tests them with orthogonal RNA/p16 assays; expert pathology and tissue processing remain shared dependencies." }, { "label": "HPV-negative reassessment and genuine negative controls", "sources": [ 17, 18, 19, 24, 25 ], "excludes_error": "Separates technical false negatives from reproducible HPV-independent squamous and glandular biology; selected-negative sampling prevents treating these reports as independent prevalence estimates." } ], "shared_failure_mode_checked": true, "note": "Eight causal or boundary lines remain after grouping shared cohorts, programmes, modalities, and assay paradigms. No single screening artifact, PCR target failure, specimen-quality problem, host confounder, vaccine-uptake bias, or model-system artifact can produce all eight. The shared limitation is definitional: 'HPV-associated' must not be assigned from the same positive result used to prove necessity." }, "redteam_synthesis": { "date": "2026-09-30", "red_team_model": "Claude (Anthropic), cross-model red team; authoring model(s) differed", "inputs": [ "persistent-high-risk-hpv-cervical-carcinoma-hsef-v54-review.md", "persistent-high-risk-hpv-cervical-carcinoma-hsef-v54-scorecard.json", "persistent-high-risk-hpv-cervical-carcinoma-hsef-v54-validation.txt", "persistent-high-risk-hpv-cervical-carcinoma-hsef-v54-preregistration.md", "README-persistent-high-risk-hpv-cervical-carcinoma-hsef-v54.txt" ], "mode": "single-version red team", "findings_total": 7, "findings_by_severity": { "critical": 0, "major": 0, "minor": 4, "editorial": 3 }, "findings_accepted": 3, "findings_partially_accepted": 1, "findings_rejected": 1, "findings_confirmed_no_defect": 2, "score_before": { "level": "Θ", "descriptor": "High predictive accuracy, minimal unresolved exceptions", "confidence": "High", "role": "primary driver" }, "score_after": { "level": "Θ", "descriptor": "High predictive accuracy, minimal unresolved exceptions", "confidence": "High", "role": "primary driver" }, "grade_changed": false, "grade_change_rationale": "No change. All 25 original citations resolved to the correct paper and every reachable numeric claim matched its primary source, so no factual correction moved a subclaim. Θ is the correct ceiling: the HSEF Ω descriptor requires necessity AND sufficiency, and HPV infection is not sufficient (most infections clear), so a necessity-only claim cannot reach Ω; Η is too low given the convergent, mutually-error-excluding evidence within the circularity-safe scope. The grade reflects evidence, not the textbook 'necessary cause' reputation.", "citations_checked": 26, "citations_corrected": 0, "citations_removed": 0, "citations_added": 1, "citations_added_detail": [ "26: Palmer et al. J Natl Cancer Inst 2024; PMID 38247547; DOI 10.1093/jnci/djad263 (Scotland invasive-cancer readout, strengthens SC4)" ], "retractions_or_eoc_found": 0, "audit_trail": "redteam/REDTEAM_REPORT.md; redteam/SYNTHESIS_CHANGE_LOG.md" }, "consensus_validation": { "completed": true, "status": "documented_historical_discovery_and_reconciliation", "provider": "Consensus", "provider_mode": "Historical browser/connector use as recorded in the source artifacts", "local_audit_date": "2026-10-09", "primary_comparison_count": null, "reported_usage": [], "grade_changed": false, "score_before": { "hsef_level": "Θ", "hsef_descriptor": "High predictive accuracy, minimal unresolved exceptions", "confidence": "High", "confidence_rationale": "The core direction is replicated across prospective cohorts, two prophylactic vaccine platforms, national invasive-cancer programmes, randomized screening, multi-target tumour assays, morphology-first pathology, genomics, and E6/E7 loss-of-function systems. Confidence is High in the near-necessity of persistent carcinogenic HPV for the common pathway and lower only for exception-free wording and continued human tumour dependence.", "rests_on_non_peer_reviewed_work": false, "rationale": "Persistent carcinogenic HPV is the primary upstream cause of nearly all common squamous and usual-type cervical carcinomas, and preventing infection changes high-grade and invasive disease as predicted. The claim stops at Θ because 'HPV-associated' is circular unless independently operationalized, most infections are not sufficient, and rare HPV-independent squamous and glandular cervical carcinomas are real." }, "score_after": { "hsef_level": "Θ", "hsef_descriptor": "High predictive accuracy, minimal unresolved exceptions", "confidence": "High", "confidence_rationale": "The core direction is replicated across prospective cohorts, two prophylactic vaccine platforms, national invasive-cancer programmes, randomized screening, multi-target tumour assays, morphology-first pathology, genomics, and E6/E7 loss-of-function systems. Confidence is High in the near-necessity of persistent carcinogenic HPV for the common pathway and lower only for exception-free wording and continued human tumour dependence.", "rests_on_non_peer_reviewed_work": false, "rationale": "Persistent carcinogenic HPV is the primary upstream cause of nearly all common squamous and usual-type cervical carcinomas, and preventing infection changes high-grade and invasive disease as predicted. The claim stops at Θ because 'HPV-associated' is circular unless independently operationalized, most infections are not sufficient, and rare HPV-independent squamous and glandular cervical carcinomas are real." }, "independent_blinded_audit": false, "raw_receipts": [ { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\hpv-cervical-carcinoma\\consensus-browser-links.json", "sha256": "ab99ec5e84d2fd06378fa52fa9f9c9d12e6f46eee7aaa27467dfe26978160b99" }, { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\hpv-cervical-carcinoma\\consensus-browser.txt", "sha256": "c75b4bf8ccc8e055854f52ca0b5e88bb76026a4eb61148e649ab2708100f9123" }, { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\hpv-cervical-carcinoma\\consensus-targeted-check.txt", "sha256": "dc9dc4827ca81560d65164ff1c1bc026c0749d2ec6766e58786cb0578d861fa7" } ], "limitations": "This verifies documented historical use and links the record to the final edition. It adds no primary-source, full-text, independence or verification credit. Original access remains limited to the source-specific record.", "existing_primary_reconciliation": { "slug": "hpv-cervical-carcinoma", "consensus_used": true, "rawproof": [ "deliverables/prepublication-enrichment-2026-10-05/website-series/hpv-cervical-carcinoma/consensus-browser.txt", "deliverables/prepublication-enrichment-2026-10-05/website-series/hpv-cervical-carcinoma/consensus-targeted-check.txt", "deliverables/prepublication-enrichment-2026-10-05/website-series/hpv-cervical-carcinoma/consensus-browser-links.json" ], "reconciliation_existing": "Yes; 9 primary identifiers matched; update says abstract/metadata checked and notes broad response irrelevance plus focused follow-up retrieval gaps.", "primary_sources_matched": [ "10451482", "17494925", "19435895", "21900119", "25100830", "32997908", "34741816", "37702216", "40347270" ], "limitations": "No independently readable body for Consensus-reported full-text details; initial broad response had irrelevant records." } } }